Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for a biomarker-matched substudy with NSCLC previously treated with ICI and platinum-based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator's choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed).…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• A
  AstraZeneca
• G
  GlaxoSmithKline
• AC
  American College of Radiology Imaging Network
• C
  Celgene
• RP
  Regeneron Pharmaceuticals
• E
  Exelixis
• JP
  Jazz Pharmaceuticals
• I
  Incyte
• EC
  ECOG-ACRIN Cancer Research Group
• E
  Eisai
• P
  PharmaMar
• G
  Genentech
• DS
  Daiichi Sankyo Europe